http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-10035189-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_796271cb56b52651a027e2cd127b661c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-683 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4084 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-683 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-40 |
| filingDate | 2000-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3ff2a2c0daea3bedd669ee95740f4fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cc934e047d60ff8c2cd03fcc20580da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a06d0827aac4b882edfa69739612e51f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a75a7072c02d825c640de21866b800ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579d55841fa55bafb765eff389294b67 |
| publicationDate | 2002-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-10035189-A1 |
| titleOfInvention | Drugs for oral administration containing 3-N-formylhydroxylaminopropylphosphonic acid esters or 3-N-acetylhydroxylaminopropylphosphonic acid esters as active ingredient |
| abstract | The drugs 3-N-formylhydroxylaminopropylphosphonic acid (fosmidomycin) and 3-N-acetylhydroxylaminopropylphosphonic acid (FR900098), which have strongly polar functional groups, have an insufficient absorption from the gastrointestinal tract. In addition, there are many esters of these active ingredients, namely the compounds of the formula (I) DOLLAR F1 in which R¶1¶ represents hydrogen and methyl, and in which R¶2¶ and R¶3¶ are selected from the group consisting of from phenyl esters, C¶1-9¶-acyloxy-C¶1-9¶-alkyl groups, phenyl-C¶1-9¶-alkyloxy-C¶1-9¶-alkyl esters, SC¶1-9¶-alkoxythio- C¶1-9¶ alkyl esters, C¶1-9¶ alkyloxybenzyl esters and cyclic esters, in which the two ester-forming oxygen atoms are connected via an alkyl chain with 1 to 5 carbon atoms and the alkyl chain with C¶1-9¶ alkyl , C¶1-9¶ alkoxy, C¶1-9¶ acyl and C¶1-9¶ acyloxy groups may be substituted as suitable prodrugs. On the one hand, these compounds are stable enough to survive the time in the gastrointestinal tract without any noteworthy splitting, on the other hand, they are largely split in the target cell. |
| priorityDate | 2000-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 109.